| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NECTIN4 |
| Uniprot No | Q96NY8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 32-349aa |
| 氨基酸序列 | GELETSDVVTVVLGQDAKLPCFYRGDSGEQVGQVAWARVDAGEGAQELALLHSKYGLHVSPAYEGRVEQPPPPRNPLDGSVLLRNAVQADEGEYECRVSTFPAGSFQARLRLRVLVPPLPSLNPGPALEEGQGLTLAASCTAEGSPAPSVTWDTEVKGTTSSRSFKHSRSAAVTSEFHLVPSRSMNGQPLTCVVSHPGLLQDQRITHILHVSFLAEASVRGLEDQNLWHIGREGAMLKCLSEGQPPPSYNWTRLDGPLPSGVRVDGDTLGFPPLTTEHSGIYVCHVSNEFSSRDSQVTVDVLDPQEDSGKQVDLVSAS |
| 预测分子量 | 36.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于NECTIN4重组蛋白的典型参考文献(示例格式，部分为模拟内容)：
1. **《Structural characterization of human NECTIN4 for targeted cancer therapy》**
- 作者：Christoph J. Lang et al.
- 摘要：解析了重组人NECTIN4蛋白的晶体结构，揭示其与抗体药物偶联物(如Enfortumab vedotin)的结合表位，为优化癌症靶向治疗提供结构基础。
2. **《NECTIN4 as a therapeutic target in solid tumors: Preclinical validation of a novel antibody-drug conjugate》**
- 作者：Sara M. Tolaney et al.
- 摘要：通过重组NECTIN4蛋白验证其在多种实体瘤(如尿路上皮癌、乳腺癌)中的高表达，并开发靶向NECTIN4的ADC药物，在临床前模型中显著抑制肿瘤生长。
3. **《Recombinant NECTIN4 extracellular domain enhances the efficacy of T-cell-mediated immunotherapy》**
- 作者：Takuro Nakamura et al.
- 摘要：证明重组NECTIN4胞外域蛋白可通过阻断免疫检查点通路(如TIGIT/CD226)，增强抗肿瘤T细胞活性，为联合免疫治疗提供新策略。
4. **《Clinical significance of serum NECTIN4 levels in metastatic urothelial carcinoma》**
- 作者：Jonathan L. Kaufman et al.
- 摘要：利用重组NECTIN4蛋白建立ELISA检测法，发现血清NECTIN4水平与尿路上皮癌患者对Enfortumab vedotin治疗的响应率及生存期显著相关。
注：以上文献为示例性内容，实际研究需通过PubMed/Google Scholar检索真实文献(关键词：NECTIN4 recombinant protein, Enfortumab vedotin, cancer therapeutics)。
Nectin-4. a member of the nectin family of cell adhesion molecules, plays a critical role in forming and maintaining epithelial cell junctions, primarily through homophilic or heterophilic interactions with other nectins or immunoglobulin-like receptors. Structurally, it consists of an extracellular domain with three immunoglobulin-like loops, a transmembrane region, and a cytoplasmic tail that interacts with intracellular signaling partners. Beyond its physiological role in tissue organization, Nectin-4 has gained attention as a biomarker and therapeutic target in cancers, particularly in triple-negative breast cancer, ovarian cancer, and urothelial carcinoma, where its overexpression correlates with tumor progression and poor prognosis.
Recombinant Nectin-4 protein refers to a lab-engineered version of the protein produced using recombinant DNA technology. This involves cloning the Nectin-4 gene into expression vectors, followed by transfection into host systems like mammalian cells (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications and functional folding. The purified protein typically retains the extracellular domain, which is essential for studying ligand-receptor interactions or therapeutic applications.
Research applications of recombinant Nectin-4 include mechanistic studies of cell adhesion, cancer metastasis, and viral entry mechanisms (e.g., measles virus exploits Nectin-4 as an epithelial receptor). Therapeutically, it serves as a target for antibody-drug conjugates (ADCs), such as enfortumab vedotin, an FDA-approved ADC for advanced urothelial cancer. Additionally, recombinant Nectin-4 is used in diagnostic assays, drug screening, and vaccine development. Its versatility underscores its importance in both basic research and clinical innovation.
×
